Homocysteine and vascular disease in diabetes: a double hit?

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Nutritional Science

Background:

• Cardiovascular disease (CVD) is a significant complication in diabetes.
• Hyperhomocysteinaemia, a condition of elevated homocysteine levels, is a potential risk factor for CVD in diabetic individuals.
• While plasma homocysteine levels are typically normal in diabetes, factors like hyperfiltration, renal dysfunction, and folate status can influence them.

Purpose of the Study:

• To investigate the association between plasma homocysteine levels and cardiovascular complications in diabetic patients.
• To determine if hyperhomocysteinaemia is a predictor of cardiovascular events and mortality in type 2 diabetes.
• To explore the potential mechanisms linking homocysteine and increased vascular risk in diabetes.

Main Methods:

• The study analyzed plasma homocysteine levels in individuals with and without diabetes.
• Correlations were examined between homocysteine concentrations and cardiovascular events, mortality, microalbuminuria, and retinopathy.
• The influence of factors such as renal function and folate status on homocysteine levels was assessed.

Main Results:

• Hyperhomocysteinaemia is linked to microalbuminuria and retinopathy in both type 1 and type 2 diabetes.
• In type 2 diabetes, plasma homocysteine concentration significantly predicts cardiovascular events and mortality, with a stronger association observed in diabetic subjects compared to non-diabetic individuals.
• Insulin resistance was not found to be a major determinant of plasma homocysteine levels.

Conclusions:

• Elevated homocysteine levels represent a significant cardiovascular risk factor in diabetic patients, potentially acting synergistically with diabetes.
• The underlying mechanisms may involve oxidative stress-induced endothelial dysfunction and alterations in vessel structure.
• Diabetic patients warrant screening for hyperhomocysteinaemia, and folic acid supplementation should be considered pending further clinical trial results.